MOTIVATION LETTER Africa has zero computational pharmacology capacity. Zero CNS drug-discovery pipelines. Zero mathematical models of addiction that account for the continent's genetic diversity, its polypharmacy burden, or its complete absence of neuroimaging infrastructure. I built the first one from a Lagos VPS with no institutional funding, no lab, and no supervisor. The Conjunctive Consolidation Threshold model is a first-principles correction to sixty years of failed dopamine-targeting addiction pharmacology. Dopamine blockade treats reward salience, not reward-memory encoding. The CCT model formalizes the tripartite interaction between dopamine D1, NMDA, and beta-adrenergic signaling as a conjunctive threshold for memory consolidation. I specified the system as coupled ODEs, validated it with RK45 integration, and confirmed all five pre-registered hypotheses: encoding probability drops from 0.855 to 0.122, an 85.8 percent reduction, with super-additivity of 12.8 percentage points. The Bayesian MCMC posterior distributions match the analytical predictions. A provisional patent is filed for Q3 2026. I built three platforms to make this stack operational. IMPRINT screens addiction liability from polypharmacy profiles. TOPOLOGIX uses persistent homology and bipartite simplicial complexes to map drug-protein interactions, with a hERG cardiotoxicity MVP validated against public benchmarks. GATE evaluates BCI neural-stimulation safety under Apache 2.0. These are not side projects. They are the infrastructure layer for a continent that has none. Emergent Ventures funds zero-to-one ideas that institutions ignore. My trajectory fits that pattern exactly. I have endorsements from Kent Berridge at Michigan, Samuel Gershman at Harvard who sponsored my arXiv account, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. I have three sole-authored preprints on OSF and Zenodo, a review article under review at Neuroscience and Biobehavioral Reviews, and a co-authored paper in Alcohol under review at Elsevier. I am applying for MSc programs starting October 2026 at MUG and Graz, Austria. This grant would fund the clinical trial architecture specified in my third preprint, the Bayesian population dynamics model that predicts individual relapse probability from pharmacogenetic data, and the computational infrastructure to run it. The CCT model is not an incremental improvement. It is a correction to the fundamental assumption that dopamine alone drives addiction. Africa needs this correction because it cannot afford the failed pharmacology of the last six decades. I need Emergent Ventures because no traditional funder funds independent researchers building first-principles neuroscience from Lagos. RESEARCH STATEMENT The central problem in addiction pharmacology is that dopamine D2 receptor antagonists reduce reward salience but do not prevent the encoding of reward-memory associations. Relapse rates remain above 60 percent across all pharmacotherapies. The field has spent sixty years optimizing the wrong target. The Conjunctive Consolidation Threshold model solves this by formalizing the neurobiological condition under which reward-memory encoding occurs. Encoding requires simultaneous activation of three receptor systems: dopamine D1 for salience gating, NMDA for calcium-dependent plasticity, and beta-adrenergic for cAMP-PKA signaling. No single pathway is sufficient. The threshold is conjunctive. I specified the model as a system of three coupled ordinary differential equations representing receptor occupancy, intracellular signaling cascade activation, and synaptic weight change. The encoding probability function is a sigmoid over the product of the three activation variables. I solved the system numerically using RK45 integration with 10,000 parameter samples drawn from physiologically plausible ranges. The results confirm that triple-target occupancy reduces encoding probability from 0.855 to 0.122, an 85.8 percent reduction. The combined effect exceeds the sum of pairwise effects by 12.8 percentage points, confirming super-additivity. All five pre-registered hypotheses H1 through H5 are confirmed. The Bayesian MCMC posterior distributions, computed with PyMC using 4 chains of 10,000 samples each, show narrow credible intervals and no divergence. The third preprint specifies the clinical trial architecture: a Bayesian adaptive design with pharmacogenetic stratification by COMT Val158Met and DRD2 Taq1A genotypes, a triple-drug combination of low-dose amisulpride, memantine, and propranolol, and a primary endpoint of cue-induced craving reduction at 12 weeks. The trial is designed for LMIC settings with no neuroimaging requirement. Outcome measures are behavioral and self-report only. The platforms I built make this tractable. IMPRINT screens addiction liability from polypharmacy profiles using the CCT threshold as the decision boundary. TOPOLOGIX computes persistent homology of drug-protein interaction networks to identify off-target binding that could disrupt the conjunctive threshold. GATE evaluates BCI stimulation parameters for safety before human trials. These platforms run on a Supabase-Postgres backend with Python ODE solvers and JavaScript frontends. I deployed them from Lagos. The provisional patent covers the core architecture: the conjunctive threshold function, the triple-target occupancy algorithm, and the pharmacogenetic stratification method. The revenue path is licensing to generic manufacturers in West Africa who currently produce dopamine antagonists without efficacy data for African populations. The CCT model gives them a rational basis for combination therapy. This research is not a model of addiction. It is a model of how the brain encodes reward-memory, and therefore a model of how to prevent it. That is the first-principles correction that the field needs and that Africa can build. PERSONAL NARRATIVE I graduated from the University of Ibadan with a B.Pharm in 2021, CGPA 5.1 out of 7.0, German equivalent 1.9. I worked as a clinical pharmacist at Ramset Pharmacy from January to March 2026, then as National Product Manager at Synthcare from March 2026 to present. I did research assistant work at the Centre for Drug Discovery, Development and Production on NMDA receptor docking with insulin, and at the Genomic Surveillance of Antimicrobial Resistance unit on AMR surveillance pipelines. None of these positions funded my independent research. I built the CCT model on a personal laptop in Lagos. The ODE solvers ran on a rented VPS. The Bayesian MCMC chains ran on Google Colab free tier. The platforms are deployed on a $10-per-month Supabase instance. I have no institutional affiliation, no grant funding, and no lab access. I have three sole-authored preprints, a review article under review, a co-authored paper under review, and endorsements from four of the top computational neuroscientists in the world. Tyler Cowen writes that the best ideas come from people who do not fit institutional molds. I am a Nigerian pharmacist who taught herself computational neuroscience from arXiv papers, built a mathematical model of reward-memory encoding, validated it with Bayesian statistics, and filed a patent on the architecture. I am applying to MSc programs in Austria because no Nigerian university offers computational neuroscience. I am applying to Emergent Ventures because it is the only funder that evaluates ideas on their merits, not on the applicant's institutional pedigree. The Africa angle is not a narrative device. It is the structural reason this work matters. Africa has 17 percent of the global population, zero computational pharmacology pipelines, and the fastest-growing addiction burden in the world. The CCT model was designed for settings with no neuroimaging, no genetic testing infrastructure, and no specialist addiction psychiatrists. The pharmacogenetic stratification uses two SNPs that cost less than $10 to genotype. The triple-drug combination uses generics that cost less than $20 per month. The behavioral endpoints require no equipment. This is not a model for Africa. It is a model from Africa, built by an African, for the conditions that Africans face. I am 29 years old. I have no PhD, no MSc, no institutional backing, and no safety net. I have a mathematical model that corrects sixty years of failed pharmacology, three platforms that implement it, a patent that protects it, and a continent that needs it. Emergent Ventures is the right programme for this stage of my career because it funds the person, not the institution. CHECKLIST - [ ] One-page proposal, approximately 370 words, as plain text or PDF - [ ] Substack post as evidence of public writing and idea dissemination - [ ] One-page CV in PDF format - [ ] Links to three preprints on OSF and Zenodo - [ ] Link to ORCID profile - [ ] Link to GitHub profile - [ ] Link to ZYCO website - [ ] Provisional patent filing reference number for Q3 2026 - [ ] Names and affiliations of endorsers: Kent Berridge, Samuel Gershman, Nathaniel Daw, Marcelo Mattar - [ ] Proof of PCN pharmacist license - [ ] University of Ibadan transcript and degree certificate - [ ] Current employment verification from Synthcare EDITOR NOTES - Eligibility risk: Emergent Ventures Africa typically funds entrepreneurs and policy innovators, not academic researchers. The application must frame CCT as an infrastructural venture, not a research project. The patent and platforms are the evidence for this framing. If the reviewer sees this as a grant for basic science, it will be rejected. - Fact to verify: The provisional patent filing date is listed as Q3 2026. If the application is submitted before the patent is filed, the language must change from "filed" to "filing in progress" or "provisional application prepared." Do not claim a filed patent that does not exist. - Gap to fill: The Substack post is listed as required evidence but no Substack URL or post title is provided in the profile. The applicant must either write a new post summarizing the CCT model for a general audience or provide the URL of an existing post. This is a non-negotiable requirement for the application. - Gap to fill: The one-page proposal word count is approximately 370 words. The motivation letter above is longer. The applicant must either submit the motivation letter as the proposal and trim it, or write a separate shorter document. The instructions say one-page proposal, not motivation letter. Clarify which document is which. - Tone risk: The personal narrative section is direct and confrontational. Tyler Cowen rewards this style, but the reviewer may find it arrogant. The applicant should decide whether to soften the tone or lean into it. Given EV's track record, leaning in is the safer bet.